RedHill Biopharma Limited
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, RedHill Biopharma Limited sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
RedHill Biopharma Limited: 13 sponsored US clinical trials, none currently recruiting.
RedHill Biopharma Limited sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 6 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cholangiocarcinoma, Extrahepatic, with 1 trials.
Top-decile sponsor footprint
RedHill Biopharma Limited ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
13 total, page 1 of 1
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
NCT04723537
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
NCT04616924
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
NCT04467840
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
NCT04414618
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
NCT03377179
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
NCT03198507
Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease
NCT03009396
ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma
NCT02757326
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
NCT02757105
BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
NCT02246439
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
NCT01980095
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
NCT01951326
ABC294640 in Treating Patients With Advanced Solid Tumors
NCT01488513
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
| Phase 3 | 6 |
How the RedHill Biopharma Limited archive is shaped
13 indexed studies, none listed as recruiting (0% open); 10 completed (77%).
Phase mix: 6 late (III/IV) vs 7 early (I/II) (balanced across stages).
Top condition: Cholangiocarcinoma, Extrahepatic (1 trial), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
RedHill Biopharma Limited: archived-pipeline peers nationwide
Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
RedHill Biopharma Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 archived trials
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this RedHill Biopharma Limited page
13 registered trials is a research-attention snapshot, not an endorsement of RedHill Biopharma Limited or any single study.
- None of RedHill Biopharma Limited's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cholangiocarcinoma, Extrahepatic is the condition RedHill Biopharma Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cholangiocarcinoma, Extrahepatic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
RedHill Biopharma Limited pipeline card: 13 registered trials from official public datasets.Report a data error.